The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. CRISPR Therapeutics AG shares valued at $51,499,918 were purchased by George Simeon on Jul 16 ’25. At $52.03 per share, George Simeon acquired 989,812 shares. The insider’s holdings grew to 1,730,179 shares worth approximately $95.32 million following the completion of this transaction.
Also, Patel Naimish sold 3,932 shares, netting a total of over 141,316 in proceeds. Following the sale of shares at $35.94 each, the insider now holds 6,068 shares.
Before that, Kulkarni Samarth had sold 10,031 shares from its account. In a trade valued at $413,578, the Chief Executive Officer traded CRISPR Therapeutics AG shares for $41.23 each. Upon closing the transaction, the insider’s holdings decreased to 10,031 shares, worth approximately $10.75 million.
As published in a research note from Evercore ISI on February 14, 2025, CRISPR Therapeutics AG [CRSP] has been rated up from an In-line to an Outperform and the price target has been revised to $99 from $60. Analysts at TD Cowen upgraded the stock from ‘”a Sell”‘ to ‘”a Hold”‘ outlook in a report released in mid February. As of February 03, 2025, H.C. Wainwright has initiated its “Buy” rating for CRSP. Earlier on August 06, 2024, Needham resumed its rating. Their recommendation was “a Buy” for CRSP stock.
Analyzing CRSP Stock Performance
On last trading session,, CRISPR Therapeutics AG [NASDAQ: CRSP] plunged -0.09% to $55.09. The stock’s lowest price that day was $54.8, but it reached a high of $56.1999 in the same session. During the last five days, there has been a drop of approximately -6.63%. Over the course of the year, CRISPR Therapeutics AG shares have dropped approximately -4.12%.
Support And Resistance Levels for CRISPR Therapeutics AG (CRSP)
RSI (Relative Strength Index) is 63.20 on the 14-day chart, showing neutral technical sentiment.
Is CRISPR Therapeutics AG subject to short interest?
Stocks of CRISPR Therapeutics AG saw a sharp rise in short interest on 2025-06-13 jumping by 0.34 million shares to 21.41 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 21.07 million shares. A jump of 1.61% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 9.74 of the overall float, the days-to-cover ratio (short ratio) jumped to 9.74.
Which companies own the most shares of CRISPR Therapeutics AG (CRSP)?
In terms of CRISPR Therapeutics AG share price expectations, FactSet research, analysts set an average price target of 65 in the next 12 months, up nearly 17.88% from the previous closing price of $55.14. Analysts anticipate CRISPR Therapeutics AG stock to reach 65 by 2025, with the lowest price target being 65. In spite of this, 8 analysts ranked CRISPR Therapeutics AG stock as Buy at the end of 2025. On August 02, 2024, Rodman & Renshaw assigned a price target of “a Buy” to the stock and initiated coverage with a $90.
